Cell Therapy Market By Clinical-use (Therapeutic Area (Malignancies, Muscoskeletal Therapies, Autoimmune Disorders, Dermatology, and Others), Cell Type (Stem Cell Therapies, BM, Blood, & Umbilical Cord-derived Stem Cells, Adipose Derived Cells, and Others), Non-stem Cell Therapies, and Research-use), By Type (Autologous Therapies and Allogenic Therapies), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI371219 | Publish Date: March 2024 | No. of Pages: 175

Global Cell Therapy Market Market Companies

  • JCR Pharmaceuticals Co. Ltd.
  • Kolon TissueGene, Inc.
  • MEDIPOST
  • Osiris Therapeutics, Inc.
  • Stemedica Cell Technologies, Inc.
  • Cells for Cells
  • NuVasive, Inc.
  • Anterogen.Co., Ltd.
  • Fibrocell Science, Inc.
  • Vericel Corporation
  • PHARMICELL Co., Ltd

Recent News:

  • In July 2022, Achilles Therapeutics, announced that it had received a $4.2 million grant from Horizon Europe, the EU's main funding initiative for research and innovation. This funding is provided to accelerate the production of personalized therapies.
  •  In May 2022, Sernova, announced collaboration with Evotec to develop cell therapy to treat insulin-dependent diabetes using induced pluripotent stem cell (iPSC)-based therapies.
  •  In February 2022, the US FDA approved the drug ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma who have not responded to refractory treatments or have relapsed after treatment.
  • In October 2021, the US FDA approved the use of brexucabtagene autoleucel (Tecartus), a CAR T treatment, for people with B-cell precursor ALL who did not respond to previous treatment (animal refractory) or the condition recurs after treatment. With this approval, brexucabtagene became the first CAR T treatment for adults with ALL.